Clinical Trial Update: Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS) [Phase 1]

View source ↗

Summary

A Phase 1 pediatric trial conducted by Emory University will assess the safety and feasibility of intramyocardial injection of VentriGel, a Ventrix extracellula…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoplastic Left Heart Syndrome

Drugs mentioned

• VentriGel (extracellular matrix hydrogel)

Snippet

Sponsor: Emory University | Conditions: Hypoplastic Left Heart Syndrome | Phase 1 | Status: NOT_YET_RECRUITING